赛莱默 XYL 深 沪
已收盘 08-01 16:00:00 美东时间
142.18
-2.440
-1.69%
华盛通- 最 高143.89
- 今 开143.69
- 成交量 202.39万股
- 最 低 140.59
- 昨 收 144.62
- 总市值 345.50亿
- 52周最高 144.83
- 市盈率 静 38.90
- 换手率 0.00%
- 52周最低 100.0746
- 委 比 -95.74%
- 总股本 2.43亿
- 历史最高 144.83
- 量 比 1.35
- 振 幅 2.28%
- 历史最低 11.5512
- 每 手 1
- 风险率 14.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stifel Maintains Buy on Xylem, Raises Price Target to $175
Stifel analyst Nathan Jones maintains Xylem (NYSE:XYL) with a Buy and raises the price target from $162 to $175.
08-02 00:22
Xylem shares are trading higher after the company reported better-than-expected Q2 financial results and raised FY25 guidance above estimates.
Xylem shares are trading higher after the company reported better-than-expected...
07-31 23:56
Xylem Raises FY2025 Adj EPS Guidance from $4.50-$4.70 to $4.70-$4.85 vs $4.63 Est; Raises FY2025 Sales Guidance from $8.700B-$8.800B to $8.900B-$9.000B vs $8.753B Est
Xylem (NYSE:XYL) raises FY2025 Adj EPS guidance from $4.50-$4.70 to $4.70-$4.85 vs $4.63 analyst estimate. Raises FY2025 sales outlook from $8.700 billion-$8.800 billion to $8.900 billion-$9.000 billion vs $8.753 billion
07-31 18:58
Xylem Q2 Adj. EPS $1.26 Beats $1.15 Estimate, Sales $2.301B Beat $2.206B Estimate
Xylem (NYSE:XYL) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.15 by 9.95 percent. This is a 15.6 percent increase over earnings of $1.09 per share from the same period
07-31 18:56
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
6 Analysts Assess Xylem: What You Need To Know
Providing a diverse range of perspectives from bullish to bearish, 6 analysts h...
07-22 06:01
美股大行评级 | 潜在涨幅94.06%！摩根大通上调BioMarin制药目标价至113美元，维持"超配"评级
今日重点评级关注：摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从108美元升至113美元；Oppenheimer：维持P10"跑赢大市"评级，目标价从20美元升至21美元
07-15 09:23
Citigroup Maintains Buy on Xylem, Raises Price Target to $152
Citigroup analyst Andrew Kaplowitz maintains Xylem (NYSE:XYL) with a Buy and raises the price target from $137 to $152.
07-15 02:47
赛莱默中国获评2025年「520社会责任日」可持续发展优秀案例
上海2025年6月30日 /美通社/ -- 6月27日晚的北京，星光灿烂，2025年「520社会责任日」倡议活动迎来高光时刻 ——「520社会责任日」可持续发展...
06-30 16:34
